Please login to the form below

Not currently logged in
Email:
Password:

Cerezyme

This page shows the latest Cerezyme news and features for those working in and with pharma, biotech and healthcare.

Sanofi rare disease drug a breakthrough, says FDA

Sanofi rare disease drug a breakthrough, says FDA

Genzyme has built the core of its business by focusing on this group, developing big-selling brands such as Gaucher therapy Cerezyme (imiglucerase alfa), Fabrazyme (agalsidase beta) for Fabry disease and

Latest news

  • Genzyme's oral Gaucher drug cleared in Europe Genzyme's oral Gaucher drug cleared in Europe

    Patients with Gaucher disease are currently started on injectable therapy with enzyme replacement drugs such as Genzyme's own Cerezyme (imiglucerase), the top-selling medicine for the rare disease with sales ... Analysts have suggested Cerdelga could

  • Orphan drugs in latest CHMP recommendations Orphan drugs in latest CHMP recommendations

    be treated with intravenous injections such as enzyme replacement treatment Cerezyme (imiglucerase), also made by Genzyme. ... Cerdelga has demonstrated it is as effective as Cerezyme in clinical trials and was approved in the US in August.

  • FDA gives green light to Genzyme’s oral Gaucher drug FDA gives green light to Genzyme’s oral Gaucher drug

    FDA gives green light to Genzyme’ s oral Gaucher drug. Oral therapy Cerdelga is set to complement intravenous Cerezyme. ... the possibility that Cerdelga could be used alongside Cerezyme as a combination regimen.

  • EMA publishes European drug shortage details EMA publishes European drug shortage details

    EMA publishes European drug shortage details. First public list contains details on Cerezyme, Fabrazyme, Increlex and Vistide. ... Drugs featured in the first version of the shortages catalogue include Sanofi/Genzyme's Cerezyme (imiglucerase) and

  • Sanofi predicts return to growth in second half Sanofi predicts return to growth in second half

    Genzyme's portfolio of rare disease therapies increased more than a quarter to 493m as restricted supplies of Gaucher disease therapy Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta) for Fabry disease caused ... Cerezyme grew 17 per cent to 171m,

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics